DEA maintains Schedule I status for psilocybin and MDMA through 2026 regardless of FDA review progress.

The DEA (the US agency that controls which drugs are legal) will keep psilocybin and MDMA in the most restricted category — Schedule I — through 2026. This means no doctor can legally prescribe them anywhere in the US under federal law. That stays true even if the FDA (the US drug regulator) makes progress reviewing them as medicines.

Scheduling follows formal FDA approval and HHS recommendation, neither finalized. Law enforcement won't preempt. The science debate doesn't change my mandate until rescheduling is law.